Physician profile
Babak Orandi
NPI 1043483191
$10,478.36
in general payments reported to CMS, 2019-2025
6 companies · $8,682 in 2025
The $8,682 reported for 2025 was more than what 90% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.00 · 2022: $71.82 · 2023: $558 · 2024: $1,155 · 2025: $8,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,475 · Food and Beverage: $1,120 · Travel and Lodging: $767 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,475.00 |
| Food and Beverage | $1,120.33 |
| Travel and Lodging | $766.94 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,533.09 | 2024-2025 | |
| Novo Nordisk INC | $483.74 | 2022-2025 | Wegovy |
| United Therapeutics Corporation | $182.93 | 2024 | Steen Solution, Tyvaso |
| Intra-Sana Laboratories | $150.00 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Lilly USA, LLC | $116.60 | 2022-2024 | Zepbound |
| Veloxis Pharmaceuticals, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Orandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.